The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by Beigene, Johnson & Johnson and Roche, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Gilles SallesDuring the Society of Hematologic Oncology (SOHO) 2023 Congress, the Lymphoma Hub spoke to Gilles Salles, Memorial Sloan Kettering Cancer Center, New York, US. We asked, What are the key takeaways and updates from SOHO 2023?
Key takeaways and updates from SOHO 2023
Firstly, Salles discusses the key session on follicular lymphoma (FL) which covered use of the Eastern Cooperative Oncology Group (ECOG) performance status, Follicular Lymphoma International Prognostic Index score, clinical parameters, and biological insights to predict outcomes in patient with FL. He then highlights the available treatments for patients experiencing disease progression within 24 months and the role of bispecific antibodies (mosenutuzumab, odronextamab, epcoritimab, and glofitamab) in FL. He concludes that monitoring patients with FL could help to identify a panel of mutations that explain the differences in response between patients.